Journal of the American Society of Hypertension
Volume 3, Issue 6 , Pages 395-402 , November 2009

An evaluation of the efficacy of olmesartan medoxomil in Black patients with hypertension

  • Thomas D. Giles, MD

      Affiliations

    • Tulane University School of Medicine, New Orleans, Louisiana, USA
    • Corresponding Author InformationCorresponding author: Thomas D. Giles, MD, Tulane University School of Medicine, 542 Tulane Avenue, Room 331, New Orleans, Louisiana 70112. Tel: 504-834-8668; fax: 504-836-0822.
    • ,
  • Suzanne Oparil, MD

      Affiliations

    • University of Alabama School of Medicine at Birmingham, Birmingham, Alabama, USA
    • ,
  • Antonia Wang, PhD

      Affiliations

    • Daiichi Sankyo, Inc., Parsippany, New Jersey, USA
    • ,
  • Robert Dubiel, PharmD

      Affiliations

    • Daiichi Sankyo, Inc., Parsippany, New Jersey, USA

Received 10 March 2009 ,Accepted 16 September 2009.

References 

  1. Volpe M, Ruilope LM, McInnes GT, Waeber B, Weber MA. Angiotensin-II receptor blockers: benefits beyond blood pressure reduction?. J Hum Hypertens. 2005;19:331–339
  2. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–2997
  3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252
  4. Weir MR, Ferdinand KC, Flack JM, Jamerson KA, Daley W, Zelenkofske S. A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives. Hypertension. 2005;46:508–513
  5. Julius S, Alderman MH, Beevers G, Dahlof B, Devereux RB, Douglas JG, et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol. 2004;43:1047–1055
  6. Levine B. Effect of eprosartan and enalapril in the treatment of black hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr Med Res Opin. 1999;15:25–32
  7. Weir MR, Smith DH, Neutel JM, Bedigian MP. Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake. Am J Hypertens. 2001;14:665–671
  8. Giles TD, Oparil S, Silfani TN, Wang A, Walker JF. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich). 2007;9:187–195
  9. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–2031
  10. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363:2049–2051
  11. Association of Black Cardiologists (ABC) Candesartan Study Group. Evaluation of candesartan cilexetil in black patients with systemic hypertension: the ABC Trial. Heart Dis. 2000;2:392–399
  12. Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol. 2003;41:1148–1155
  13. Flack JM, Saunders E, Gradman A, Kraus WE, Lester FM, Pratt JH, et al. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther. 2001;23:1193–1208
  14. Kalinowski L, Dobrucki IT, Malinski T. Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases. Circulation. 2004;109:2511–2517
  15. Malhotra S, Poole J, Davis H, Dong Y, Pollock J, Snieder H, et al. Effects of NOS3 Glu298Asp polymorphism on hemodynamic reactivity to stress: influences of ethnicity and obesity. Hypertension. 2004;44:866–871
  16. Kurian AK, Cardarelli KM. Racial and ethnic differences in cardiovascular disease risk factors: a systematic review. Ethn Dis. 2007;17:143–152
  17. Richardson AD, Piepho RW. Effect of race on hypertension and antihypertensive therapy. Int J Clin Pharmacol Ther. 2000;38:75–79
  18. Douglas JG. Clinical guidelines for the treatment of hypertension in African Americans. Am J Cardiovasc Drugs. 2005;5:1–6
  19. Gibbons GH. Physiology, genetics, and cardiovascular disease: focus on African Americans. J Clin Hypertens (Greenwich). 2004;6:11–18
  20. Patel DA, Li S, Chen W, Srinivasan SR, Boerwinkle E, Berenson GS. G-6A polymorphism of the angiotensinogen gene and its association with left ventricular mass in asymptomatic young adults from a biethnic community: the Bogalusa Heart Study. Am J Hypertens. 2005;18:1437–1441
  21. Kumar A, Li Y, Patil S, Jain S. A haplotype of the angiotensinogen gene is associated with hypertension in African Americans. Clin Exp Pharmacol Physiol. 2005;32:495–502
  22. Zhu X, Chang YP, Yan D, Weder A, Cooper R, Luke A, et al. Associations between hypertension and genes in the renin-angiotensin system. Hypertension. 2003;41:1027–1034
  23. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich). 2001;3:283–291, 318
  24. Le MT, Pugsley MK, Vauquelin G, Van Liefde I. Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor. Br J Pharmacol. 2007;151:952–962
  25. Yanagisawa H, Amemiya Y, Kanazaki T, Shimoji Y, Fujimoto K, Kitahara Y, et al. Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds. J Med Chem. 1996;39:323–338
  26. Mire DE, Silfani TN, Pugsley MK. A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol. 2005;46:585–593
  27. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393–404

 Supported by Daiichi Sankyo, Inc. Dr. Thomas D. Giles received grant/research support from Novartis. Dr. Giles serves as a consultant for Novartis, Forest Laboratories, Daiichi Sankyo, Inc., sanofi-aventis, Bristol-Myers Squibb, and NicOx. Dr. Suzanne Oparil is the recipient of grants-in-aid from Daiichi Sankyo, Inc., Forest Laboratories, Gilead, Novartis, Pfizer, and Takeda. Dr. Oparil is a consultant for Boehringer Ingelheim, Daiichi Sankyo, Inc., NicOx, Novartis, sanofi-aventis, and The Salt Institute. Drs. Antonia Wang and Robert Dubiel are both employees of Daiichi Sankyo, Inc.

PII: S1933-1711(09)00129-6

doi: 10.1016/j.jash.2009.09.002

Journal of the American Society of Hypertension
Volume 3, Issue 6 , Pages 395-402 , November 2009

Article Tools

* Image Usage & Resolution